Strs Ohio Decreases Stock Position in Aadi Bioscience, Inc. (NASDAQ:AADI)

Strs Ohio cut its position in Aadi Bioscience, Inc. (NASDAQ:AADI – Get Rating) by 26.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,500 shares of the company’s stock after selling 900 shares during the quarter. Strs Ohio’s holdings in Aadi Bioscience were worth $35,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in AADI. Legal & General Group Plc purchased a new position in shares of Aadi Bioscience in the second quarter valued at $34,000. Royal Bank of Canada purchased a new position in shares of Aadi Bioscience in the first quarter valued at $49,000. American International Group Inc. purchased a new position in shares of Aadi Bioscience in the second quarter valued at $83,000. JPMorgan Chase & Co. bought a new position in Aadi Bioscience during the 2nd quarter valued at $95,000. Finally, Knott David M Jr bought a new position in Aadi Bioscience during the 2nd quarter valued at $173,000. 67.09% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, LADENBURG THALM/SH SH reduced their price objective on shares of Aadi Bioscience to $47.00 in a research note on Tuesday, November 15th.

Aadi Bioscience Price Performance

NASDAQ AADI opened at $12.80 on Monday. Aadi Bioscience, Inc. has a 12 month low of $11.00 and a 12 month high of $21.15. The company has a market capitalization of $312.26 million, a price-to-earnings ratio of -4.30 and a beta of 1.26. The company’s fifty day moving average price is $12.89 and its two-hundred day moving average price is $13.05.

Aadi Bioscience (NASDAQ:AADI – Get Rating) last issued its earnings results on Wednesday, November 9th. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07. The company had revenue of $4.25 million for the quarter, compared to analysts’ expectations of $3.60 million. Aadi Bioscience had a negative net margin of 569.57% and a negative return on equity of 44.28%. As a group, analysts anticipate that Aadi Bioscience, Inc. will post -2.86 EPS for the current year.

About Aadi Bioscience

(Get Rating)

Aadi Bioscience, Inc operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancers patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai on November 2007 and is headquartered in Los Angeles, CA.